Article Details
Retrieved on: 2024-04-17 14:38:59
Tags for this article:
Click the tags to see associated articles and topics
Summary
Goldman Sachs's investment advice reflects a strategic shift favoring companies like Syngene International that may benefit from the "China+1" business strategy, enhancing their position in the global pharmaceutical industry including markets like India.
Article found on: www.news18.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here